Search Results - "Piatek, Caroline I"

Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature by Vergara-Lluri, Maria E., MD, Piatek, Caroline I., MD, Pullarkat, Vinod, MD, Siddiqi, Imran N., MD, PhD, O'Connell, Casey, MD, Feinstein, Donald I., MD, Brynes, Russell K., MD

“…Summary Autoimmune myelofibrosis (AIMF) is a distinct clinicopathological entity associated with diffuse bone marrow fibrosis and a benign clinical course…”
Get full text

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria by Peipert, John Devin, Kulasekararaj, Austin G., Gaya, Anna, Langemeijer, Saskia M. C., Yount, Susan, Gonzalez-Fernandez, F. Ataulfo, Ojeda Gutierrez, Emilio, Martens, Christa, Sparling, Amy, Webster, Kimberly A., Cella, David, Tomazos, Ioannis, Ogawa, Masayo, Piatek, Caroline I., Wells, Richard, Sicre de Fontbrune, Flore, Röth, Alexander, Mitchell, Lindsay, Hill, Anita, Kaiser, Karen

“…Background Eculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains…”
Get full text

An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians by Granatowicz, Austin, Piatek, Caroline I, Moschiano, Elizabeth, El-Hemaidi, Ihab, Armitage, Joel D, Akhtari, Mojtaba

“…Chronic myeloid leukemia (CML) accounts for approximately 15% of adult leukemias. Forty percent of patients with CML are asymptomatic, in whom the disease is…”
Get full text

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study by Kulasekararaj, Austin G., Hill, Anita, Rottinghaus, Scott T., Langemeijer, Saskia, Wells, Richard, Gonzalez-Fernandez, F. Ataulfo, Gaya, Anna, Lee, Jong Wook, Gutierrez, Emilio Ojeda, Piatek, Caroline I., Szer, Jeff, Risitano, Antonio, Nakao, Shinji, Bachman, Eric, Shafner, Lori, Damokosh, Andrew I., Ortiz, Stephan, Röth, Alexander, Peffault de Latour, Regis

“…Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was noninferior to eculizumab administered every 2 weeks in…”
Get full text

One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab by Kulasekararaj, Austin G., Hill, Anita, Langemeijer, Saskia, Wells, Richard, González Fernández, F. Ataúlfo, Gaya, Anna, Ojeda Gutierrez, Emilio, Piatek, Caroline I., Mitchell, Lindsay, Usuki, Kensuke, Bosi, Alberto, Brodsky, Robert A., Ogawa, Masayo, Yu, Ji, Ortiz, Stephan, Röth, Alexander, Lee, Jong Wook, Peffault de Latour, Régis

“…Ravulizumab every 8 weeks showed non‐inferiority to eculizumab every 2 weeks in a 26‐week, phase 3, randomized controlled trial in adults with paroxysmal…”
Get full text

Management of immune-mediated cytopenias in pregnancy by Piatek, Caroline I, El-Hemaidi, Ihab, Feinstein, Donald I, Liebman, Howard A, Akhtari, Mojtaba

“…Abstract Immune-mediated cytopenias are a well-described complication of pregnancy. Appropriate recognition and treatment are important in order to limit…”
Get full text

Value of routine staging imaging studies for patients with stage III breast cancer by Piatek, Caroline I., Ji, Lingyun, Kaur, Chandan, Russell, Christy A., Tripathy, Debu, Church, Terry, Sposto, Richard, Sener, Stephen F., Garcia, Agustin A.

“…Background and Objectives Routine staging imaging studies (RSIS) are optional in stage III breast cancer (BC). The impact of RSIS on treatment decisions and…”
Get full text

Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors by Piatek, Caroline I., Raja, Grace L., Ji, Lingyun, Gitlitz, Barbara Jennifer, Dorff, Tanya B., Quinn, David I., Hu, James, El-Khoueiry, Anthony B., Pham, Huyen Q., Roman, Lynda, Garcia, Agustin A.

“…Purpose To determine the maximal tolerated dose (MTD) of the combination of weekly temsirolimus and every other week vinorelbine in patients with advanced or…”
Get full text

Further Characterization of Thromboembolic Events and Association with Platelet Count Occurring during the Avatrombopag Immune Thrombocytopenia (ITP) Clinical Development Program by Piatek, Caroline I., Jamieson, Brian, Kolodny, Scott

“…Background: ITP management often requires subsequent therapy beyond current first line treatments (corticosteroids or intravenous immunoglobulin). The use of…”
Get full text

Genetic Screens for Enhancers of brahma Reveal Functional Interactions Between the BRM Chromatin-Remodeling Complex and the Delta-Notch Signal Transduction Pathway in Drosophila by Armstrong, Jennifer A, Sperling, Adam S, Deuring, Renate, Manning, Laurina, Moseley, Sarah L, Papoulas, Ophelia, Piatek, Caroline I, Doe, Chris Q, Tamkun, John W

“…The Drosophila trithorax group gene brahma (brm) encodes the ATPase subunit of a 2-MDa chromatin-remodeling complex. brm was identified in a screen for…”
Get full text

Characterization of Thromboembolic Events Occurring during the Avatrombopag Immune Thrombocytopenia (ITP) Clinical Development Program by Piatek, Caroline I., Jamieson, Brian, Vredenburg, Michael

“…Background: ITP management often requires subsequent therapy beyond current first line treatments (corticosteroids or intravenous immunoglobulin). The use of…”
Get full text

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study (FORWARD) of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia by Kuter, David J., Piatek, Caroline I., Saikali, Khalil, Dummer, Wolfgang

Get full text

Screening of Corticosteroid-Induced Osteoporosis in Patients with Immune Thrombocytopenia or Warm Autoimmune Hemolytic Anemia in the Outpatient Setting by Ebia, Matthew I, Martinez, Leslie, Piatek, Caroline I.

“…Introduction: Corticosteroids (CS) are the standard first line treatment for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (WAIHA)…”
Get full text

Ordering Patterns of Thrombophilia Testing and Its Appropriateness by Chow, Lydia, Garvey, Sarah, Ma, Thomas, Hudgins, Jay, Piatek, Caroline I.

“…Background Despite society recommendations to limit thrombophilia testing, this testing is often sent inappropriately. The results of thrombophilia testing…”
Get full text

Improving Delays in Obtaining Lenalidomide at a Large Safety Net Hospital by Pai, Jonathan S., Patel, Ronak, Algaze, Sandra, Martinez, Leslie, Piatek, Caroline I.

“…Introduction: Lenalidomide is an immunomodulatory agent used primarily in the management of multiple myeloma and non-Hodgkin's lymphomas. Owing to the risks of…”
Get full text

Efficacy and Safety of Subcutaneous Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Prior Intravenous Eculizumab: 2-Year Follow-up by Piatek, Caroline I, Sicre De Fontbrune, Flore, Sahin, Fahri, Füreder, Wolfgang, Gualandro, Sandra Fatima, Barcellini, Wilma, Ogawa, Masayo, Ortiz, Stephan, Ozol-Godfrey, Ayca, Szer, Jeff, Yenerel, Mustafa

“…Background : Subcutaneous (SUBQ) ravulizumab, administered weekly via an on-body delivery system, showed pharmacokinetic (PK) non-inferiority to intravenous…”
Get full text

A US Retrospective Observational Study of Rituximab Use in Cold Agglutinin Disease by Piatek, Caroline I, Murakhovskaya, Irina, Karaouni, Alia, Miles, Gandarvaka, Heller, Carrie, Lucia, Jacqueline, Patel, Reena, Tyma, Jennifer, Yoo, Ronnie, Gertz, Morie A.

“…Background Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia (AIHA). Rituximab is approved for treatment of B-cell lymphoma and severe…”
Get full text

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data by Kulasekararaj, Austin, Griffin, Morag, Piatek, Caroline I, Shammo, Jamile, Nishimura, Jun-Ichi, Patriquin, Christopher J., Schrezenmeier, Hubert, Gaya, Anna, Patel, Yogesh, Liu, Peng, Filippov, Gleb, Sicre De Fontbrune, Flore, Risitano, Antonio M, Lee, Jong-Wook

“…Background C5 inhibitors eculizumab (Ecu) and ravulizumab (Rav) have transformed the natural history of paroxysmal nocturnal hemoglobinuria (PNH). Ecu resulted…”
Get full text

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis by Piatek, Caroline I, Lee, Jong-Wook, Griffin, Morag, Nishimura, Jun-Ichi, Patriquin, Christopher J., Schrezenmeier, Hubert, Barcellini, Wilma, Shammo, Jamile, Gaya, Anna, Patel, Yogesh, Liu, Peng, Myrén, Karl-Johan, Sicre De Fontbrune, Flore, Panse, Jens, Kulasekararaj, Austin

“…Background Treatment with complement C5 inhibitors eculizumab (Ecu) and ravulizumab (Rav) inhibits terminal complement activity, improving hemoglobin (Hgb)…”
Get full text

Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies by Peffault De Latour, Regis, Szer, Jeffrey, Kulasekararaj, Austin, Kim, Jin Seok, Piatek, Caroline I., Kulagin, Alexander D., Hill, Anita, Wang, Jimmy, Yu, Ji, Ogawa, Masayo, Schrezenmeier, Hubert, Lee, Jong Wook

“…Background: In the two largest phase 3 studies in patients with paroxysmal nocturnal hemoglobinuria (PNH), ravulizumab given every 8 weeks was noninferior to…”
Get full text